Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

CD8+ T cell states in human cancer: insights from single-cell analysis

Nature Reviews Cancer volume 20, pages 218–232 (2020)Cite this article

Subjects

Abstract

The T cell infiltrates that are formed in human cancers are a modifier of natural disease progression and also determine the probability of clinical response to cancer immunotherapies. Recent technological advances that allow the single-cell analysis of phenotypic and transcriptional states have revealed a vast heterogeneity of intratumoural T cell states, both within and between patients, and the observation of this heterogeneity makes it critical to understand the relationship between individual T cell states and therapy response. This Review covers our current knowledge of the T cell states that are present in human tumours and the role that different T cell populations have been hypothesized to play within the tumour microenvironment, with a particular focus on CD8+ T cells. The three key models that are discussed herein are as follows: (1) the dysfunction of T cells in human cancer is associated with a change in T cell functionality rather than inactivity; (2) antigen recognition in the tumour microenvironment is an important driver of T cell dysfunctionality and the presence of dysfunctional T cells can hence be used as a proxy for the presence of a tumour-reactive T cell compartment; (3) a less dysfunctional population of tumour-reactive T cells may be required to drive a durable response to T cell immune checkpoint blockade.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Model of intratumoural CD8+ T cell states.
Fig. 2: Model for the development of CD8+ T cell dysfunction and the effect of PD1 blockade.
Fig. 3: Hallmarks of intratumoural tumour-reactive CD8+ T cells.

Similar content being viewed by others

References

  1. Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310 (1996).

    CAS  PubMed  Google Scholar 

  2. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).

    CAS  PubMed  Google Scholar 

  3. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

    CAS  PubMed  Google Scholar 

  4. Fridman, W. H., Pagès, F., Saut’s-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).

    CAS  PubMed  Google Scholar 

  5. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

    CAS  PubMed  Google Scholar 

  10. Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl Med. 6, 254ra128 (2014).

    PubMed  Google Scholar 

  11. Robert, L. et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20, 2424–2432 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl Med. 6, 238ra70 (2014).

    PubMed  PubMed Central  Google Scholar 

  13. Robert, L. et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 3, e29244 (2014).

    PubMed  PubMed Central  Google Scholar 

  14. Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451–460 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696–701 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016). The first single-cell transcriptome and TCR analysis of the TME in human melanoma, dissecting the major T cell states and tumour-specific programmes.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789.e18 (2019). Single-cell transcriptome and TCR analysis in human melanoma describing a dysfunctional axis made up of cells that are transcriptionally related and show TCR sharing, as well as a separate cytotoxic population. The dysfunctional T cells identified contain a highly proliferative subset and are indicative of the presence of a tumour-reactive T cell repertoire.

    CAS  PubMed  Google Scholar 

  22. Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018). Single-cell transcriptome analysis in human melanoma indicating that TCF7-expressing T cells in human cancer are associated with response to ICB. Furthermore, the study shows that CD39 − and TIM3 − T cells display reactivity against mouse colon carcinoma cells in the presence of anti-PD1.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290–1297 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Baitsch, L. et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350–2360 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 1–11 (2018). This study defines a T cell subset in human NSCLC with high expression of PD1 that is enriched for tumour reactivity, that expresses markers of T cell activation and that appears predictive of clinical response to anti-PD1 therapy.

    Google Scholar 

  26. Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade. Proc. Natl Acad. Sci. USA 105, 15016–15021 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356.e16 (2017). Single-cell transcriptome and TCR analysis of T cells in HCC showing the distribution and connectivity between T cell states in tumour tissue, adjacent normal tissue and blood, and that also provides evidence for the presence of cell state diversity within T cell clones.

    CAS  PubMed  Google Scholar 

  29. Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018). Single-cell transcriptome analysis of T cells in NSCLC, adjacent normal tissue and blood showing the distribution of T cell states in these tissues and their relatedness based on TCR sharing between cell states inside and outside the tumour. Moreover, this study provides evidence for dysfunctionality as a gradual state.

    CAS  PubMed  Google Scholar 

  30. Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019). Single cell transcriptome and TCR analysis of T cells in human BCC suggest the presence of novel T cell clonotypes within the dysfunctional (‘exhausted’) compartment after ICB.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268–272 (2018). Single-cell transcriptome and TCR analysis of T cells in microsatellite-stable and microsatellite-instable colorectal tumours addressing the clonotypic relationships between intratumoural dysfunctional cells and T cells with other cell states that reside in the tumour, normal tissue or blood.

    CAS  PubMed  Google Scholar 

  32. Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308.e36 (2018). Single-cell transcriptome analysis of immune cells in human breast cancer demonstrating that intratumoural T cells reside along a continuum that is driven by activation and terminal differentiation. In addition, cell state diversity is shown both between and within T cell clones.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Clarke, J. et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J. Exp. Med. 216, 2128–2149 (2019). Single-cell transcriptome analysis of T cells in human NSCLC describing a PD1-expressing and TIM3-expressing T RM cell subset that contains a highly proliferative subset and is enriched in lesions of patients responding to anti-PD1 therapy.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018). Single-cell transcriptome analysis of T cells in two human breast cancer samples characterizing T RM cells that express, among other genes, inhibitory receptor genes such as PDCD1 and CTLA4.

    CAS  PubMed  Google Scholar 

  35. Fehlings, M. et al. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat. Commun. 8, 562 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).

    CAS  PubMed  Google Scholar 

  38. Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330–1345.e18 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Salerno, F. & Wolkers, M. C. T-cells require post-transcriptional regulation for accurate immune responses. Biochem. Soc. Trans. 43, 1201–1207 (2015).

    CAS  PubMed  Google Scholar 

  40. Salerno, F. et al. Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells. Oncoimmunology 8, e1532762 (2019).

    PubMed  Google Scholar 

  41. Dieu-Nosjean, M. C. et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260–275 (2016).

    CAS  PubMed  Google Scholar 

  42. Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).

    PubMed  Google Scholar 

  43. Kunz, D. J., Gomes, T. & James, K. R. Immune cell dynamics unfolded by single-cell technologies. Front. Immunol. 9, 1435 (2018).

    PubMed  PubMed Central  Google Scholar 

  44. Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019). A mouse melanoma study showing the importance of a low dysfunctional (‘progenitor exhausted’) T cell population marked by TCF1 expression and required for response to anti-PD1 therapy.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Lanitis, E., Dangaj, D., Irving, M. & Coukos, G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann. Oncol. 28, xii18–xii32 (2017).

    CAS  PubMed  Google Scholar 

  46. Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019). Unbiased analysis of the tumour reactivity of TCRs in human cancer lesions providing formal evidence that human colorectal and ovarian tumours contain high proportions of bystander T cells.

    CAS  PubMed  Google Scholar 

  47. Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018). This study demonstrates the presence of virus-specific bystander T cells in human lung and colorectal tumours. Intratumoural bystander T cells were characterized by a lack of CD39 expression, suggesting that CD39 can be used to help distinguish tumour-reactive T cells from bystander cells.

    CAS  PubMed  Google Scholar 

  48. Erkes, D. A. et al. Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function independently of PD-1 expression. J. Immunol. 198, 2979–2988 (2017).

    CAS  PubMed  Google Scholar 

  49. Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmunology 1, 409–418 (2012).

    PubMed  PubMed Central  Google Scholar 

  50. Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Pasetto, A. et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4, 734–743 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389–401 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Inozume, T. et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33, 956–964 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, (2018). This study identifies CD103 and CD39 as markers of tumour-reactive T cells across multiple human cancer types.

  57. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Singer, M. et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166, 1500–1511.e9 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1014–1030.e19 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Martínez-Usatorre, A., Donda, A., Zehn, D. & Romero, P. PD-1 blockade unleashes effector potential of both high- and low-affinity tumor-infiltrating T cells. J. Immunol. 201, 792–803 (2018).

    PubMed  Google Scholar 

  61. Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M. & Kastenmüller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018).

    CAS  PubMed  Google Scholar 

  62. Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019). A mouse study providing evidence for the role of TCF1-expressing PD1 + CD8 + T cells in tumour control on anti-PD1 and anti-CTLA4 combination therapy.

    CAS  PubMed  Google Scholar 

  63. Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1−CD8+ tumor-infiltrating T cells. Immunity 50, 181–194.e6 (2019). A mouse study that describes a PD1-low subset of T cells that responds to ICB and identifies Tcf7 expression to be required for response to anti-PD1 and anti-TIM3 combination therapy.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Utzschneider, D. T. et al. T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections. Immunity 45, 415–427 (2016).

    CAS  PubMed  Google Scholar 

  65. Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Wu, T. et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1, eaai8593 (2016).

    PubMed  PubMed Central  Google Scholar 

  67. Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487–502.e15 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Brummelman, J. et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J. Exp. Med. 215, 2520–2535 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335–1347 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Wei, S. C. et al. Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity 50, 1084–1098.e10 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).

    PubMed  PubMed Central  Google Scholar 

  72. Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35, 238–255.e6 (2019).

    CAS  PubMed  Google Scholar 

  73. Jiao, S. et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 179, 1177–1190.e13 (2019).

    CAS  PubMed  Google Scholar 

  74. Kim, H. J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2, 91–98 (2014).

    CAS  PubMed  Google Scholar 

  75. Ahrends, T. & Borst, J. The opposing roles of CD4+ T cells in anti-tumour immunity. Immunology 154, 582–592 (2018).

    CAS  PubMed Central  Google Scholar 

  76. Braumüller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361–365 (2013).

    PubMed  Google Scholar 

  77. Qin, L. et al. Insights into the molecular mechanisms of T follicular helper-mediated immunity and pathology. Front. Immunol. 9, 1884 (2018).

    PubMed  PubMed Central  Google Scholar 

  78. Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132–1148 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765.e17 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Giordano, M. et al. Molecular profiling of CD 8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 34, 2042–2058 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Li, J., He, Y., Hao, J., Ni, L. & Dong, C. High levels of Eomes promote exhaustion of anti-tumor CD8+ T cells. Front. Immunol. 9, 2981 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Chihara, N. et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature 558, 454–459 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Paley, M. A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220–1225 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269 (2019).

    CAS  PubMed  Google Scholar 

  86. Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Blank, C. U. et al. Defining ‘T cell exhaustion’. Nat. Rev. Immunol. 19, 665–674 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Welch, J. D. et al. Single-cell multi-omic integration compares and contrasts features of brain cell identity. Cell 177, 1873–1887.e17 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865–868 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Wang, C., Singer, M. & Anderson, A. C. Molecular dissection of CD8+ T-cell dysfunction. Trends Immunol. 38, 567–576 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Philip, M. & Schietinger, A. Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Curr. Opin. Immunology 58, 98–103 (2019).

    CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Y. Lubling and M. Logtenberg for input and insightful discussions. This work was supported by ERC AdG SENSIT to T.N.S. and the Dutch Cancer Society Bas Mulder Award to D.S.T.

Author information

Authors and Affiliations

  1. Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands

    Anne M. van der Leun, Daniela S. Thommen & Ton N. Schumacher

Authors
  1. Anne M. van der Leun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela S. Thommen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ton N. Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.M.v.d.L researched data for the article. A.M.v.d.L, D.S.T. and T.N.S. jointly discussed data and co-wrote the article.

Corresponding author

Correspondence to Ton N. Schumacher.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information

Nature Reviews Cancer thanks Z. Zhang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Glossary

Tumour-specific T cell reactivity

The capacity of a T cell to recognize tumour cells, regardless of its ability to perform effector function.

Single-cell RNA sequencing

Gene expression profiling method that allows unbiased transcriptome analysis of individual cells.

Clonotype

The unique T cell receptor (TCR) sequence formed by both the TCR α-chain and the TCR β-chain.

Predictive biomarkers

Certain measurements (for example, T cell count or expression level of a marker gene) to make a risk estimate of the response of a patient to therapy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Leun, A.M., Thommen, D.S. & Schumacher, T.N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer 20, 218–232 (2020). https://doi.org/10.1038/s41568-019-0235-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41568-019-0235-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer